CAS 1453084-36-0

Mirvetuximab

CAS: 1453084-36-0

Mirvetuximab, a monoclonal antibody targeting FOLR1/FRα, treats ovarian and FRα-positive cancers, often paired with platinum-based drugs.

Purity: > 95% - > 95%

Color and Shape: Liquid

Molecular weight: 145.96 kDa

Ref: TM-T76766

Mirvetuximab

CAS: 1453084-36-0

Mirvetuximab is an antibody-drug conjugate (ADC), which is a targeted cancer therapy designed to deliver cytotoxic agents specifically to cancer cells. This ADC is derived from a monoclonal antibody that specifically binds to the folate receptor alpha (FRα), a protein overexpressed in certain types of cancer cells, including ovarian cancer. The mode of action involves the binding of Mirvetuximab to FRα on the cancer cell surface, followed by internalization of the complex. Once inside the cell, the cytotoxic drug is released, leading to cell death.Mirvetuximab is primarily utilized in the treatment of FRα-positive ovarian cancer, particularly in patients with platinum-resistant disease. By exploiting the differential expression of FRα, Mirvetuximab can deliver lethal doses of chemotherapy directly to the cancer cells, thereby minimizing systemic toxicity. This targeted approach enhances the therapeutic index of the treatment, improving efficacy while reducing adverse effects typically associated with conventional chemotherapy. Ongoing clinical trials are exploring its potential in other FRα-expressing malignancies, making it a pivotal component in the advancement of personalized cancer therapy.

Ref: 3D-CLA1417